Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label Phase I/II Trial Aiming to Assess the Safety and Clinical Activity of Tarlatamab in Combination With Metronomic Temozolomide in Adolescents and Adults' Patients With High Grade Brain Tumors

NCT07243470 is registered in ClinicalTrials.gov with Centre Leon Berard as lead sponsor.

NCT NCT07243470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07243470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label Phase I/II Trial Aiming to Assess the Safety and Clinical Activity of Tarlatamab in Combination With Metronomic Temozolomide in Adolescents and Adults' Patients With High Grade Brain Tumors
Lead sponsor
Centre Leon Berard
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 4, 2025
Completion date
October 31, 2030
Enrollment
70 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

cns tumor, adult, cns tumor, childhood, glioma